Accelerated Formulation Development of Monoclonal Antibodies (mAbs) and mAb-Based Modalities: Review of Methods and Tools. (April 2015)

• Record Type: Journal Article
• Authors: Razinkov, Vladimir I.; Treuheit, Michael J.; Becker, Gerald W.
• Other Names: Howes Rob guest-editor.; McGivern Joseph G. guest-editor.
• Is Part Of: Journal of biomolecular screening. Volume 20:Number 4(2015)
• Page Start: 468
• Page End: 483
• Publication Date: 2015-04
• Subjects: monoclonal antibodies -- high-throughput methods -- formulation development -- quality by design -- design of experiment -- drug development; Drugs -- Analysis -- Periodicals; Drugs -- Testing -- Periodicals; Biomolecules -- Analysis -- Periodicals; 572.36
• DOI: 10.1177/1087057114565593
• Languages: English
• ISSNs: 1087-0571

Abstract

More therapeutic monoclonal antibodies and antibody-based modalities are in development today than ever before, and a faster and more accurate drug discovery process will ensure that the number of candidates coming to the biopharmaceutical pipeline will increase in the future. The process of drug product development and, specifically, formulation development is a critical bottleneck on the way from candidate selection to fully commercialized medicines. This article reviews the latest advances in methods of formulation screening, which allow not only the high-throughput selection of the most suitable formulation but also the prediction of stability properties under manufacturing and long-term storage conditions. We describe how the combination of automation technologies and high-throughput assays creates the opportunity to streamline the formulation development process starting from early preformulation screening through to commercial formulation development. The application of quality by design (QbD) concepts and modern statistical tools are also shown here to be very effective in accelerated formulation development of both typical antibodies and complex modalities derived from them.